Emodinanthrone  (Synonyms: EmodAN)

Emodinanthrone (EmodAn) is a MARCH7 stabilizer that inhibits ferroptosis (EC₅₀=70 nM). Emodinanthrone is also a precursor to Emodin (HY-14393) and possesses antibiotic activity. Emodinanthrone directly binds to MARCH7 and blocks its ubiquitination-mediated degradation at the K608 site; this action enhances MARCH7-mediated K48 ubiquitination and degradation of NCOA4, as well as its regulation of the intracellular localization of TFR1 via K63 ubiquitination, thereby reducing the intracellular labile iron pool and blocking ferroptosis. Emodinanthrone demonstrates in vivo cardioprotective effects and exhibits a favorable safety profile. Emodinanthrone is applicable to research on ferroptosis-related cardiovascular diseases, including Doxorubicin (HY-15142A)-induced cardiomyopathy and myocardial ischemia-reperfusion injury^[1][2][3][4].

Emodinanthrone (5 μM; 12 h) inhibits RSL3 (0.20 μM)-induced ferroptosis in HT-1080 cells, enhances cell viability, and reduces intracellular Fe²⁺ and lipid ROS levels^[1].
Emodinanthrone (0.3125-5 μM; 12 h) dose-dependently enhances the viability of RSL3 (0.20 μM)-treated HT-1080 cells, exhibiting an anti-ferroptotic EC₅₀ of 70 nM; it also demonstrates cytotoxicity against HT-1080 and HeLa cells, with IC₅₀ values ??of 35.58 μM and 19.40 μM, respectively^[1].
Emodinanthrone (5 μM; 12 h) fails to inhibit RSL3-induced ferroptosis in MARCHF7-knockdown/knockout HT-1080 cells, nor does it reduce lipid ROS levels in these cells^[1].
Emodinanthrone (5 μM; 24 h) inhibits the RSL3-induced ubiquitination-mediated degradation of MARCH7 in HT-1080 cells, thereby stabilizing the MARCH7 protein, while having no effect on the ubiquitination and degradation of the MARCH7-K608R mutant^[1].
Emodinanthrone (5 μM; 24 h) stabilizes the MARCH7 protein in HeLa cells and downregulates NCOA4 while upregulating the protein levels of FTH1 and GPX4^[1].
Emodinanthrone (5 μM; 24 h) enhances the GFP-MARCH7 fluorescence signal in HeLa-GFP-MARCH7 cells, thereby stabilizing the MARCH7 protein^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Emodinanthrone (0.5, 1, 2 mg/kg; i.p.; once daily; for 7 consecutive days) in Normal C57BL/6J male mice, did not affect mouse body weight, organ weights, liver and kidney function, or cardiac biochemical parameters; no significant toxic side effects observed^[1].
Emodinanthrone (1 mg/kg; i.p.; 72 h prior to DOX modeling and continued for 3 days; and an additional 14 days) in Doxorubicin (DOX)-induced cardiomyopathy model in C57BL/6J male mice, induces serum levels of CK-MB, AST, and LDH; alleviates myocardial inflammation and fibrosis; reduces myocardial iron overload and lipid ROS; restores myocardial expression of MARCH7, GPX4, and FTH1 while downregulating NCOA4; and improves mouse survival rate^[1].
Emodinanthrone (1 mg/kg; i.p.; once as a pretreatment prior to I/R modeling) in Myocardial Ischemia-Reperfusion (I/R) injury model in C57BL/6J male mice, reduces serum levels of AST, CK-MB, BUN, CK, and LDH; alleviates myocardial inflammation and fibrosis; reduces myocardial iron overload and lipid ROS; and restores myocardial expression of MARCH7, GPX4, and FTH1 while downregulating NCOA4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

256.25

C₁₅H₁₂O₄

491-60-1

Solid

Light yellow to yellow

O=C1C2=C(C=C(C)C=C2O)CC3=CC(O)=CC(O)=C13

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Huang W, et al. Stabilizing MARCH7 as a ferro-guardian against ferroptosis. Cell. 2026 Apr 27:S0092-8674(26)00388-0.

  [2]. Jin-Young Chung, et al. Expression, purification, and characterization of AknX anthrone oxygenase, which is involved in aklavinone biosynthesis in Streptomyces galilaeus. J Bacteriol. 2002 Nov;184(22):6115-22.  [Content Brief]

  [3]. T Ubbink-Kok, et al. Inhibition of electron transfer and uncoupling effects by emodin and emodinanthrone in Escherichia coli. Antimicrob Agents Chemother. 1986 Jul;30(1):147-51.  [Content Brief]

  [4]. M K Wang, et al. Triterpenoid saponins from Berneuxia thebetica. Phytochemistry. 1998 Aug;48(8):1411-4.  [Content Brief]